Showing results (11-20 of 56) with videos related to
Sort By:
Pageof 6
The Oncologist|June 14, 2015
U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate CancerYang-Min Ning, Michael Brave, V Ellen Maher, et al.The Oncologist|March 25, 2010
FDA approval summary: temsirolimus as treatment for advanced renal cell carcinomaVirginia E Kwitkowski, Tatiana M Prowell, Amna Ibrahim, et al.The Oncologist|October 29, 2002
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acidMartin H Cohen, Ramzi Dagher, Donna J Griebel, et al.Journal of Clinical Pharmacology|December 29, 2006
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicityRoshni P Ramchandani, Yaning Wang, Brian P Booth, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2018
US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic AssessmentsSuparna B Wedam, Julia A Beaver, Laleh Amiri-Kordestani, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2020
An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate CancerMichael Brave, Chana Weinstock, Jamie R Brewer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastasesAmna Ibrahim, Nancy Scher, Grant Williams, et al.European Urology|June 4, 2023
A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell CarcinomaDaniel Lee, Haley Gittleman, Chana Weinstock, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 29, 2020
FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast CancerSuparna Wedam, Lola Fashoyin-Aje, Xin Gao, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 3, 2026
Outcome-specific risk factors challenge universal dementia prevention priorities: Findings from the Egyptian Dementia Network RegistryShimaa A Heikal, Eman M Khedr, Gharib Fawi, et al.Pageof 6